Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment
American Journal of Clinical Dermatology · 2025
DOI: 10.1007/s40257-024-00913-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Dermatology, 2025. Verfasst von Joe Gorelick und 5 weiteren Autor:innen. Beteiligte Einrichtung: California Skin Institute, San Jose-Los Gatos, CA, USA. jgorelick1@me.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-13, Antibodies, Monoclonal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LEO Pharma Inc.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response of AD are traditionally reported through clinical assessments including the Eczema Area and Severity Index or Investigator's Global Assessment. These clinical rating scales are visual assessments used in clinical trials to denotate AD severity. Alternatively, biomarkers open the potential to further enhance diagnosis of AD, assess disease status and severity, and potentially enable tailored treatment options for patients. Biomarkers can be classified according to their clinical use, clinical presentation, and underlying/endogenous molecular mechanisms. Specifically, interleukin (IL)-13, which has been shown to be a key biomarker in AD pathogenesis, can be used for prediction of AD development and to monitor clinical severity/response to treatment. Treatment with tralokinumab, a human monoclonal antibody that binds directly to-and subsequently blocks signaling of-IL-13, has been shown to reduce inflammation, re-balance the skin microbiome, and improve the skin barrier in patients with AD. In this review, key AD-related biomarkers, the role of IL-13 in driving AD pathogenesis, and the impact of IL-13 inhibition by tralokinumab on other AD-related biomarkers are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- California Skin Institute, San Jose-Los Gatos, CA, USA. jgorelick1@me.com.
- First OC Dermatology, Irvine, CA, USA.
- LEO Pharma Inc, Madison, NJ, USA.
- LEO Pharma A/S, Ballerup, Denmark.
- David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Förderung
- LEO Pharma Inc
Zitieren
APA
Gorelick, J., Nguyen, A., Schneider, S. K. R., Martel, B. C., Madsen, D. E., & Armstrong, A. W. (2025). Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00913-9
Vancouver
Gorelick J, Nguyen A, Schneider SKR, Martel BC, Madsen DE, Armstrong AW. Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment. American Journal of Clinical Dermatology. 2025. doi:10.1007/s40257-024-00913-9
BibTeX
@article{Gorelick2025,
author = {Gorelick, Joe and Nguyen, Andrea and Schneider, Shannon K R and Martel, Britta C and Madsen, Daniel E and Armstrong, April W},
title = {Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment},
journal = {American Journal of Clinical Dermatology},
year = {2025},
doi = {10.1007/s40257-024-00913-9}
}
EUVIMED